Growth Metrics

AbCellera Biologics (ABCL) Other Working Capital Changes (2020 - 2026)

AbCellera Biologics filings provide 7 years of Other Working Capital Changes readings, the most recent being $1.7 million for Q1 2026.

  • Quarterly Other Working Capital Changes rose 123.78% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$8.1 million through Mar 2026, up 52.09% year-over-year, with the annual reading at -$17.1 million for FY2025, 188.01% down from the prior year.
  • Other Working Capital Changes hit $1.7 million in Q1 2026 for AbCellera Biologics, up from -$3.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $16.7 million in Q2 2025 and bottomed at -$23.4 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is -$2.2 million, with a median of -$3.1 million recorded in 2025.
  • Peak annual rise in Other Working Capital Changes hit 2036.84% in 2024, while the deepest fall reached 1598.13% in 2024.
  • AbCellera Biologics' Other Working Capital Changes stood at $5.5 million in 2022, then tumbled by 354.78% to -$13.9 million in 2023, then surged by 64.5% to -$4.9 million in 2024, then surged by 37.93% to -$3.1 million in 2025, then surged by 156.71% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Other Working Capital Changes are $1.7 million (Q1 2026), -$3.1 million (Q4 2025), and -$23.4 million (Q3 2025).